Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05011058
Title An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Viracta Therapeutics, Inc.

peripheral T-cell lymphoma

nasal type extranodal NK/T-cell lymphoma

Hodgkin's lymphoma


diffuse large B-cell lymphoma



CHR-3996 + Valganciclovir

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | DEU | CAN

No variant requirements are available.